HIGHLIGHTS
- who: Report et al. from the USA Research, Butler Health System, Butler, USA Medical Oncology, University of Pittsburgh, Pittsburgh, USA, . have published the research work: Review began 09/22/2022 Review ended 09/29/2022 Published 10/04/2022 u00a9 Copyright, in the Journal: (JOURNAL) of October/04,/2022
- what: Patients with tumors that have classic epidermal growth factor receptor (EGFR) mutations were offered adjuvant erlotinib versus observation, and this study has now been 2022 Ashish et_al Cureus 14(10): e29922. Analysis the authors advocate the need for EGFR mutation testing in all NSCLC disease . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.